ESMO

News

ESMO: J&J cues up phase 3 for Rybrevant in colorectal cancer

Johnson & Johnson is planning a phase 3 programme for Rybrevant in colorectal cancer as a follow-up to its first indication in non-small cell lung cancer (NSCLC), after reporting encour

News

ESMO: NIAGARA backs Imfinzi in bladder cancer, but will FDA?

AstraZeneca has revealed the data for Imfinzi in muscle-invasive bladder cancer (MIBC) that it hopes will be enough to secure FDA approval – although the jury is out on that.

News

ESMO: Incyte's PD-1 treads new ground in anal cancer

Incyte's first attempt to get FDA approval for its PD-1 inhibitor Zynyz for squamous cell carcinoma of the anal canal (SCAC) was knocked back by the FDA, but new data could get the programm

News

ESMO: Enhertu shows its worth in brain metastases

Women with HER2-positive breast cancer can be treated with AstraZeneca and Daiichi Sankyo's Enhertu, regardless of whether their cancer has spread to the brain, according to a new study.

Oncology

ESMO 2024 – Today’s oncological roots are branching

What could a tree possibly reveal about the European Society for Medical Oncology (ESMO)?

Oncology

ADCs shine at ESMO ’23, as pharma makes case for early immun...

Antibody-drug conjugates (ADCs) took centre stage at the European Society of Medical Oncology (ESMO) Congress in Madrid 20th-24th October, which was back at full capac

ESMO: J&J cues up phase 3 for Rybrevant in colorectal cancer

ESMO: NIAGARA backs Imfinzi in bladder cancer, but will FDA?

ESMO: Incyte's PD-1 treads new ground in anal cancer

ESMO: Enhertu shows its worth in brain metastases

ESMO 2024 – Today’s oncological roots are branching

ADCs shine at ESMO ’23, as pharma makes case for early immun...

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

ESMO

Editor's Picks